The effect of increasing doses of cyclosporin A (CsA) given to mice infected intravenously with Mycobacterium bovis BCG was investigated. Development of both tuberculin hypersensitivity and acquired antituberculous resistance was suppressed in a dose-responsive manner. Daily dosages at 100 mg/kg of body weight prevented any reduction in the BCG counts within the lungs, liver, or spleen. This effect was associated with lowered nonspecific resistance to a Listeria monocytogenes challenge and a decline in specific protective immunity adoptively transferred to naive recipients. CsA treatment had no effect on antilisterial activity by activated macrophages or on the antituberculous immunity expressed by specific memory T cells. CsA treatment inhibited the ability of BCG-vaccinated mice to produce gamma interferon (IFN--y) after a secondary stimulation with live BCG or with lipopolysaccharide. Spleen cells from BCG-infected mice which were exposed to daily treatment with CsA showed reduced IFN--y production in response to purified protein derivative or concanavalin A stimulation, suggesting that the immunosuppressive effect of CsA on BCG-infected mice was expressed by inhibiting the development of effector T cells responsible for the production of IFN-y.
Cyclosporin A (CsA) is a potent immunosuppressive drug which acts on defined subpopulations of immunocompetent cells without expressing appreciable myelotoxicity (5) . Although it preferentially affects expressor-T-cell activity, it can also depress plaque-forming-cell responses to DNPFicoll (16) or pokeweed mitogen (2) and reduce monokine (interleukin-1) production (6) . Because of these properties, CsA has been widely used to prolong allograft retention and prevent graft-versus-host disease (23) . However, the same properties may also affect the level of host resistance which can be expressed against a number of intracellular bacterial and viral pathogens (13, 22) .
Acquired antituberculous resistance is mediated by a population of sensitized T cells which activate blood monocytes entering a developing tubercle in such a way that they can limit the further growth of virulent tubercle bacilli in vivo (17) . Recently, it was shown that daily doses of CsA effectively inhibited epithelioid cell formation and depressed tuberculin hypersensitivity in Mycobacterium bovis BCGvaccinated guinea pigs (10) . Other studies have shown suppression of T-cell-mediated antilisterial immunity in sublethally challenged mice (14) . In the present study, the effect of daily CsA treatments on T-cell responsiveness in BCG-infected animals was assessed in terms of both specific and nonspecific antibacterial immunity. This was then correlated with the production of gamma interferon (IFN-y) both in vivo and in vitro. The results indicate that CsA suppresses the development of antituberculous immunity if it is administered early in the infection, whereas later it can only affect the production of IFN--y by the sensitized T-cell population within the infected spleen.
MATERIALS AND METHODS Animals. Specific-pathogen-free female C57BL/6 x DBA/2 (B6D2) F1 hybrid mice were bred at the Trudeau Animal Breeding Facility, Saranac Lake, N.Y., and housed under barrier conditions. Groups of mice 7 to 9 weeks old and averaging 20 g in weight at the beginning of the experiment were used. They were fed sterilized commercial mouse chow and acidified water ad libitum (8) .
Drugs. CsA was kindly provided by J. F. Borel, Sandoz Ltd., Basel, Switzerland. The powder was dissolved at 60°C in sterile olive oil at a concentration of 20 mg/ml (10) . The mice received up to 21 daily injections subcutaneously (s.c.), usually at a dosage of 100 mg/kg of body weight. Controls received an equivalent amount of olive oil only.
Bacteria. M. bovis BCG Pasteur (TMC 1011) and Mycobacterium tuberculosis Erdman (TMC 107) were obtained from the Trudeau Mycobacterial Culture Collection, Saranac Lake, N.Y. Both organisms were grown in modified Sauton liquid medium at 37°C, harvested during the late logarithmic growth phase, and stored in 1-ml ampoules at -70°C (9) .
Listeria monocytogenes EGD (serotype 3B) was passaged in mice (18) and then grown in tryptic soy broth (Difco Laboratories, Detroit, Mich.). The growth was harvested during the late logarithmic phase and stored in 1-ml aliquots at -70°C.
A frozen ampoule was thawed, briefly homogenized, and diluted appropriately in sterile saline. The mice were infected intravenously (i.v.) via a lateral tail vein with known numbers of viable organisms suspended in 0.2 ml of sterile saline (8) .
Bacterial growth in vivo. Organs were removed aseptically and homogenized separately in sterile cold saline. The number of viable bacteria was determined by plating serial 10-fold dilutions on Middlebrook 7H11 agar (Difco) and counting the colonies after incubation at 37°C for 2 to 3 weeks in sealed plastic bags. In some experiments, the Middlebrook 7H11 agar was supplemented with 2 ,ug of 2-thiophenecarboxylic acid hydrazide (Aldrich Chemical Co., Inc., Milwaukee, Wis.) to inhibit the growth of M. bovis BCG (8) . The (20) . Cell viability was determined by trypan blue dye exclusion and was always greater than 80%.
Age-and sex-matched syngeneic recipients were subjected to 500 rads of whole-body gamma irradiation (19) Treatment of spleen cells with anti-Thy-1.2 antibody and complement. Spleen cells (107/ml) were treated with a 1:10 dilution of anti-Thy-1.2 antibody (supernatant from 30-H12 hybridoma) and rabbit serum (Low-Tox-M rabbit complement; Accurate Chemical and Scientific Corp., Westbury, N.Y.) for 60 min at 37°C in a one-step procedure, washed twice, standardized, and infused into sublethally irradiated recipients (19 (20) . One day before cell harvest, the mice were injected i.v. with 150 mg of cyclophosphatmide per kg (Mead-Johnson, Evansville, Ill.).
IFN--y production. Assays for IFN--y production were performed as described previously (21) Production in vitro was measured by removing spleens from BCG-infected mice and preparing single-cell suspensions in RPMI 1640 medium containing 2% heat-inactivated fetal calf serum. The cells were washed twice and suspended at a concentration of 107 cells per ml in RPMI 1640 medium containing 5% fetal calf serum, 1 mM L-glutamine, 100 U of penicillin per ml, and 100 ,ug of streptomycin per ml. Each cell suspension (2 ml) was placed into six-well cluster dishes (Costar, Cambridge, Mass.) and incubated at 37°C in 5% C02-enriched air for 24 h in the presence of concanavalin A (ConA) (Type IV; Sigma Chemical Co., St. Louis, Mo.) or PPD at the concentrations indicated in Table 5 . Supernatants from triplicate wells were pooled and stored at -20°C until the IFN activity could be assayed as described previously (12) .
Antibody neutralization assay. A microtiter assay was used to determine IFN activity; the L929B strain of L cells and vesicular stomatitis virus were used as the challenge (12) .
Each assay included the murine IFN-y international standard (G-002-904-511), and the IFN--y titers were corrected to this standard. The antibody neutralization assay (11) (Table 1) . Daily doses of 100 mg/kg were routinely used in the subsequent studies to suppress the development of tuberculin hypersensitivity and to delay the ability of the host defenses to limit further growth of the BCG inoculum in vivo. The differences (log10) between the CsA-treated (group 5) and control (group 1) mice on day 21 were 0.56 for the spleen and 0.82 for the lungs (Table 1) , both of which were highly significant (P < 0.001).
The control mice developed positive DTH responses by day 14 of the BCG infection, after which the number of viable BCG bacilli recovered from the spleen started to decline (Fig. 1) . However, the corresponding lung counts did not begin to drop until after 28 days. On the other hand, the CsA-treated mice showed continued growth of BCG in both the spleen and lungs throughout the entire experimental period, although some elimination of BCG from the liver was noted with time ( Fig. 1) . None of the CsA-treated mice developed positive DTH responses as long as the drug treatment was continued. In mice in which CsA injections were discontinued after 21 days, the growth behavior of BCG changed at about the time the mice developed a positive tuberculin response (Fig. 1) , which then showed a substantial increase in all of the CsA-treated groups (rebound phenomenon).
A second series of experiments was then performed to determine the effect of CsA treatment on an established BCG infection. Drug injections were started 28 days after BCG vaccination, by which time the mice had developed substantial levels of resistance to the vaccinating infection itself. The CsA injections were continued in these mice until day 55. Once again, the CsA treatment suppressed the tuberculin response in these animals and also reversed the earlier decline in the number of viable BCG within the spleen, liver, and lungs (Fig. 1) . This decline continued in the untreated controls.
Effect of CsA treatment on nonspecific resistance. The effect of daily CsA injections on nonspecific resistance was then examined because it is known that acquired antituberculous resistance increases the ability of the host to kill the unrelated challenge organism, L. monocytogenes (5, 7) . The growth curves shown in Fig. 2 indicate that as the number of viable BCG within the spleen began to decline (7 to 10 days) there was an increase in nonspecific resistance which could be ablated by CsA treatment. This suggests that CsA inhibits or blocks the macrophage activation which normally occurs during the course of BCG infection (7). BCG-vaccinated mice were able to kill 90 to 99% of L. monocytogenes within the first 6 h after an i.v. challenge (Fig. 3) . After this initial decline, the surviving organisms began to multiply in vivo for at least the next 24 h. Mice vaccinated with BCG some 21 days previously and then treated with 100 mg of CsA per kg immediately before the Listeria challenge still showed sig-VOL. 55, 1987 ._. nificant nonspecific resistance in both the liver and spleen, at levels comparable to those seen in the drug-free controls. Thus, the increased level of nonspecific resistance induced by the BCG vaccine did not seem to be affected by CsA treatment given immediately before challenge (Fig. 3) . This occurred despite the fact that the tuberculin responses in these mice were substantially depressed by such treatment (an increase in footpad thickness of 0.2 mm as opposed to 0.47 ± 0.06 mm for the controls). These results suggest that the CsA treatment did not affect the listericidal activity of macrophages already present in the vaccinated host.
Effect of CsA treatment on protective immunity. Splenic T cells harvested from BCG-infected mice, half of which were subjected to daily CsA treatments, were tested for their ability to transfer antituberculous immunity to sublethally irradiated syngeneic recipients. There were significant reductions (10-fold or more) in the numbers of viable M. tuberculosis, after i.v. challenge, in the spleens of recipient mice which received BCG-immune T cells compared with those in control mice infused with an equivalent number of normal T cells (Table 2) . However, when the T cells were harvested from BCG-infected donors which had been treated with CsA from day -2 to day 20 of the vaccinating infection, no such transferred immunity could be detected. Thus, the BCG-induced immunity could be effectively blocked by this drug. On the other hand, when the splenic T cells were harvested from mice infected 42 days previously with BCG but given the CsA treatment only for 21 days before harvest, substantial protection (60% of that seen in the BCG-infected controls) was observed (Table 2) . Thus, an already established protective immunity induced by an earlier BCG vaccination was largely CsA resistant. This experiment also showed that, after the withdrawal of the CsA treatment, these mice quickly recovered full ability to express protective immunity against M. tuberculosis challenge.
Effect of CsA treatment on memory T cells. Finally, the effect of CsA treatment was examined with an established memory-T-cell population. Spleen cells were harvested after 60 days of isoniazid chemotherapy from mice infected for 90 days. T cells harvested from these mice transferred substantial levels of protective immunity to the sublethally irradi- Mice were infected i.v. with 106 CFU of BCG on day 0. +, Immunized; -, not immunized.
CsA (100 mg/kg per day) was injected s.c. for indicated periods. d Difference from controls is statistically significant (P < 0.001). e Difference from controls is statistically significant (P < 0.01).
ated syngeneic recipients (Table 3 ) despite the absence of any detectable vaccinating infection. This response was also cytoxan resistant and could therefore be considered solely due to memory T cells (20) . Exposure of these mice to 7 days of CsA treatment before harvest did not affect the transfer of antituberculous immunity mediated by the memory T cells (Table 3) .
Effect of CsA on IFN production by BCG-infected mice.
BCG-vaccinated mice produced substantial amounts of IFN (beginning on day 7 and peaking on day 21) in response to a secondary BCG infection (Fig. 4) . Neutralization tests performed with the resulting sera indicated that it was exclusively an IFN-y response. CsA treatment of the BCGvaccinated mice either from day -1 to day 20 or from days 14 to 20 completely suppressed the ability of these mice to produce IFN-y in response to challenge with either BCG or LPS (Table 4) . On the other hand, when IFN--y production was examined by using lymphocyte cultures which had been established in vitro from these BCG-infected mice, both PPD and ConA stimulation were found to induce substantial levels of IFN-y, compared with undetectable titers for spleen cells harvested from uninfected controls (Fig. 5 ). This effect was maximal on day 14 of the primary infection. In these experiments, IFN--y production, which had been induced by either PPD or ConA stimulation, could be completely inhibited if the CsA treatment was given from the time of the BCG vaccination (Table 5) . However, IFN--y production was also significantly depressed by CsA treatment given from days 14 to 20 of the BCG infection.
DISCUSSION
The immunosuppressive effect of CsA for BCG-infected mice, with respect to both the development of tuberculin hypersensitivity and the expression of acquired antituberculous resistance, was clearly dose dependent (Table 1) , which seems to be in agreement with the findings of earlier studies (14, 16) . Repeated doses of the drug given at the 100-mg/kg level completely suppressed the early expression of antibacterial resistance to the continued development of the BCG infection. However, if the CsA treatment was delayed until after the infected mice had acquired a substantial level of antibacterial immunity, the ability of the host defenses to continue to eliminate the BCG population from the tissue was partially impaired (Fig. 1 ). This appears to be consistent with earlier reports that CsA treatment could ablate the antilisterial immunity of sublethally infected mice (14, 22) . Antituberculous immunity depends upon the interaction of specifically sensitized T cells and the blood-derived monocytes which enter the developing tubercle (3, 18) . It was important in the present study to determine whether the CsA treatments exerted their immunosuppressive effect on this process by impairing T-cell sensitization or by blocking macrophage activation. To do this, we first examined the effect of drug treatment regimens initiated at various intervals during the course of the vaccinating BCG infection. As can be seen from the data in Fig. 2B , treatment of the mice with CsA from the time of the BCG vaccination completely prevented the expression of nonspecific antilisterial resistance. However, drug treatment of activated macrophages just before harvest had little or no such effect (Fig. 3) . Thus, the CsA treatment appears to exert its immunosuppressive effect on the inductive phase of the T-cell response, since there was little effect on established memory-T-cell activity, as determined in an adoptive immune system (Table 3) . Such a conclusion seems to be compatible with earlier reports indicating that CsA could inhibit effector-T-cell development in mice developing an experimental allergic encephalomyelitis (4).
T-cell activation occurs in response to the infected macrophages, which process the triggering mycobacterial sensitins while also secreting the monokine interleukin-1. Thus, the immunocompetent T cells entering the infected lesion receive two signals from the macrophage and then begin to produce T-cell growth factor (interleukin-2), as well as a number of other lymphokines which can bring about the activation of blood monocytes entering the tubercle (18) . CsA treatment appears to inhibit lymphokine production (6) and may therefore inhibit both mitogen-and alloantigeninduced IFN--y production in vitro (15) . However, it is still unclear how this drug exerts its immunosuppressive effect within the actively infected animal. The present data suggest that the drug depresses production of IFN-y by interfering with the production of specifically sensitized T cells. The importance of IFN--y production in the induction of antilisterial activity has already been established (12) ; the present 
